{
  "docId": "019de076-c164-739c-925e-e97b24983f20",
  "docSlug": "45699c5d62cd10656fd74cee2718d284",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 45 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 45,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "Slide 18 of a presentation deck.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-c164-739c-925e-e97b24983f20/18",
  "deckHref": "/decks/019de076-c164-739c-925e-e97b24983f20",
  "deckJsonHref": "/decks/019de076-c164-739c-925e-e97b24983f20.json",
  "deckAnchorHref": "/decks/019de076-c164-739c-925e-e97b24983f20#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.67,
        "w": 0.13,
        "x": 0.03,
        "y": 0.22
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a87ee845-0486-4f92-8651-4d87aed3bbb2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.67,
        "w": 0.33,
        "x": 0.16,
        "y": 0.22
      },
      "kind": "list",
      "text": "Gracell cell therapy manufacturing platform: Shorter manufacturing time, Increased manufacturing capacity, Lower cell dose required, May improve safety, Enhanced T-cell fitness, Potential to improve outcomes",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cf545a2b-60ef-4515-81bc-4f451a79a9da",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.18,
        "x": 0.52,
        "y": 0.45
      },
      "kind": "metric",
      "text": "100% ORR at all dose levels",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "853dfe8a-155b-424b-8bdd-2e928d18bab0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.18,
        "x": 0.75,
        "y": 0.45
      },
      "kind": "metric",
      "text": "95%+ MRD negativity 6-12 mo. after infusion",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8bec6892-2653-4223-91c0-6c114a91123a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.41,
        "x": 0.52,
        "y": 0.71
      },
      "kind": "paragraph",
      "text": "Strengthening haematology portfolio and pipeline: Calquence | AZD0486 | AZD0305 | GC012F | AZD9829 | AZD3470",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e2bfaf9-c0ce-46f1-9ac9-543386dea27b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "1. N = 22. Data cut-off 1 October 2023. Chen X et al. Oral #1022 presented at American Society of Hematology 2023.",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8c9d72a3-d847-4cdf-b617-2c2b015baa2e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.75,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "Gracell acquisition furthers our position in CAR-T and haematology",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f69fe993-6124-4b9c-bee6-5f621bbb2a12",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.48,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Oncology – R&D highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b5e338e-24be-4d9d-b2a0-428cc16d6042",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "353ef9e0-4eef-451a-afe8-3e5b5fb1e97c",
      "evidence": "list/bullet: Gracell cell therapy manufacturing platform: Shorter manufacturing time, Increased manufacturing capacity, Lower cell dose required, May improve safety, Enhanced T-cell fitness, Potential to improve outcomes",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 26,
      "from": 10,
      "beatId": "43aa94ba-8d07-4798-99cd-6d40ae4b13e2",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The document provides an overview of AstraZeneca's financial results and pipeline success",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}